Search

Introduction: The peroxisome proliferator-activated receptor gamma (PPARgamma), a transcriptor factor, regulates immunological and metabolic processes, which are important for carbohydrate and lipid metabolism. Various polymorphic forms of PPARgamma may promote diabetes mellitus and diabetic complications., Aim of the Work: The assessment of TNFalpha gene expression in peripheral blood monocytes, serum TNFalpha concentration and anti-GAD and ICA antibodies in relation to the polymorphism Pro12Ala in patients with 2 diabetes., Patients and Methods: 58 patients with type 2 diabetes (average age 59.0 +/- 11 years) and 18 healthy people were examined. The Pro12Ala polymorphism of PPARy gene were assessed using mini-sequence technic SnaPshot [ABIPRISM-310]. The TNFalpha gene expression were estimated using real-time PCR [Applied Bio-systems]. The TNFalpha concentration [Quantikin Immunoassay, R&D Systems] and ICA and GAD antibodies [immunofluorescence method, DRG] were evaluated in venous blood., Results: A heterozygotous genotype Pro12Ala was estimated in 32 patients and a homozygotous genotype Pro12Pro in 21. Only 6 patients were positive for GAD antibodies and only 6 patients for ICA antibodies. The TNFalpha concentration in serum and the TNFalpha gene expression in monocytes did not refer to the Pro12ala polymorphism of PPARy and neither to antibodies., Conclusion: 1) The TNFalpha concentration in serum and the TNFalpha gene expression in monocytes do not refer to the Pro12ala polymorphism of PPARgamma in patients with type 2 diabetes. 2) The Pro12Ala genotype do not influence autoimmunologic processes of diabetes.

Unlabelled: The peroxisome proliferator-activated receptor gamma (PPARgamma) influences wide on metabolism and atheromatosus processes in vessels. The common polymorphic form of PPARy, Pro12Ala, could promote diabetes mellitus and diabetic vascular complications., Aim of Work: The assessment of indicators of endothelium destruction in patients with diabetes mellitus t.2 in relation to the polymorphism Pro12Ala of PPARgamma., Patients and Methods: Circulating blood endothelium cells (immunofluorescens method with MoAb CLB-HEC19), thrombomodulin (Asserchrom Immunoassay) and polymorphism Pro12Ala [minisequence technic SnaPshot (Applera); ABI+PRISM310] were investigated in 58 patients with diabetes mellitus typ 2 and 22 healthy persons. Fibrinogen, uric acid, lipids, HbA1c, glucose, insulin concentration, blood pressure, BMI and WHR were evaluated too., Results: The significant higher systolic (137.92 +/- 15.88 vs 122.0 +/- 15,67 [mmHg]; p < 0.025) and diastolic (85.00 +/- 7.38 vs 75.50 +/- 7.61 [mmHg]; p < 0.011) was determined in the group of healthy people, who have got a homozygous genotyp Pro12Pro in comparison with heterozygous genotyp Pro12Ala. The significant higher value of HbA1c was determined in the patients with diabetes mellitus t.2, who have got genotyp Pro12Ala in comparison with genotyp Pro12Pro (7.01 +/- 1.54 vs 8.39 +/- 1.81 [%]; p < 0.006). There was any significant difference for others parameters. Among people, which have got genotyp Pro12Pro there was significant difference between healthy and patients for circulating blood endothelium cells (2.19 +/- 1.53 vs 0.78 +/- 0.09 [EC/ml]; p < 0.009). On the contrary among people with genotype Pro12Ala there was not significant difference between healthy and patients for circulating blood endothelium cells (2.95 +/- 1.64 vs 1.61 +/- 1.08; p = 0.077 [EC/ml])., Conclusions: 1) The polymorphism Pro12Ala is not connected with the endothelium destruction. 2) Other researches are necessary to estimate influence of mutated allele on the control of diabetes. 3) The genotyp Pro12Pro promotes higher blood pressure by healthy people.